ArticleNeurology(R) neuroimmunology & neuroinflammation2025
Multiple Sclerosis in the Emergency Department: A Retrospective Case-Control Study in a Large US Center.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Short-term associations between ambient air pollution and emergency department visits for Parkinson disease, multiple sclerosis, migraine, and seizure in California, 2005-2018.Environmental epidemiology (Philadelphia, Pa.) · 2026Article
- Predictors of high- versus low-intensity first-line multiple sclerosis treatments.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThe reasons for people with multiple sclerosis (MS) to access emergency services are understudied in the era of high-efficacy disease-modifying therapies (DMTs). Many people with MS live with multiple comorbidities and/or experience social determinants of health, which may affect their emergency department (ED) use. The aim of this study was to identify the reasons and risk factors for ED visits among patients with known MS, including sociodemographic characteristics, comorbidity burden, and DMT efficacy category.
methodsA retrospective case-control study was conducted at the Massachusetts General Hospital, Boston. Patients with MS were analyzed in a 1:2 ratio of cases (patients with at least one ED visit) and controls (no ED visits) during the study time frame June 2019-December 2023. Regression models were constructed to assess the association of predefined variables-sex, age, race, insurance type, comorbidities as a Charlson Comorbidity Index (CCI), and DMT efficacy category-with the likelihood of an ED visit.
resultsOf 1,462 evaluated people with MS, 900 were randomly selected and included: 300 cases and 600 controls. Most patients were female (70.7% cases, 74.7% controls) and White (79.0% cases, 87.2% controls). Cases had a higher mean CCI score (0.83 points) compared with controls (0.05 points). Many people with MS were not taking a DMT (64.3% cases, 39.5% controls). ED utilization showed that 52.0% of patients had a single visit, with COVID-19 being the most common diagnosis (4.2%). 10.3% of people with MS who went to the ED had more than 5 visits during the study time frame. In a multivariable model, higher CCI score was the strongest predictor of ED visits (odds ratio [OR] = 4.23, DISCUSSION: Specific risk factors for ED use occur in people with known MS. Comprehensive management of comorbidities and clinical pathways to reassess the high number of people with MS in the ED who do not take a DMT should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.